Rituximab in Treating Patients With Hodgkin's Lymphoma

INCLUSION CRITERIA * Age ≥ 3 years * Lymphocyte-predominant Hodgkin's disease (LPHD) of B-cell lineage * Biopsy-confirmed expression of CD20 antigen * At least one tumor mass measuring \> 1.0 cm in largest dimension * No evidence of active infection * Subjects at high risk of Hepatitis B virus (HBV) infection should be screened prior to enrollment. * Performance status of 0 to 2 * Absolute neutrophil count (ANC) \> 1500/mL * Platelet count \> 50,000/mL * Serum creatinine (Cr) \< 1.5 x upper limit of normal (ULN) * Alkaline phosphatase \< 2 x ULN, unless related to primary disease * Bilirubin \< 2 x ULN, unless related to primary disease * Aspartate transaminase (AST) and alanine transaminase (ALT) \< 2 x ULN, unless related to primary disease * Subjects must be able to read and sign Institutional Review Board-approved informed consent EXCLUSION CRITERIA * Life expectancy at least 12 weeks * Evidence of other active malignancies other than cured carcinomas in situ of the cervix or basal cell carcinoma of the skin * Active HBV infection or hepatitis. * Serious non-malignant disease (eg, congestive heart failure, or active uncontrolled bacterial, viral, or fungal infections) * Concomitant or treatment within prior 4 weeks with radiotherapy or chemotherapy (within prior 6 weeks for nitrosourea compounds) * Concurrent treatment with prednisone or other systemic steroid medication * Treatment with any investigational drug within 30 days prior to entry into the study * Treatment with any investigational drug within 5 half-lives of that drug prior to entry into the study * Major surgery, other than diagnostic surgery, within 4 weeks * Any other conditions which, in the opinion of the investigator and/or sponsor, would compromise other protocol objectives * Female patients must be of non-childbearing potential or using adequate contraception with a negative pregnancy test at study entry